AAPL341.15+1.65 (+0.49%) ▲|ABBV286.36-2.60 (-0.90%) ▼|ABT99.16-3.29 (-3.21%) ▼|ACN239.63+0.51 (+0.21%) ▲|ADBE256.33-0.40 (-0.16%) ▼|AMAT407.98+3.00 (+0.74%) ▲|AMD542.98+8.24 (+1.54%) ▲|AMGN436.48-2.46 (-0.56%) ▼|AMT179.77-3.79 (-2.06%) ▼|AMZN260.04-2.59 (-0.99%) ▼|AVGO333.80-0.57 (-0.17%) ▼|AXP321.75+3.41 (+1.07%) ▲|BA191.87+1.40 (+0.74%) ▲|BAC50.73+0.09 (+0.18%) ▲|BKNG157.99-5.93 (-3.62%) ▼|BLK1,132.51+3.83 (+0.34%) ▲|BMY61.25-0.44 (-0.71%) ▼|BNY145.28+1.03 (+0.71%) ▲|BRK-B541.72+1.90 (+0.35%) ▲|C122.60+0.09 (+0.07%) ▲|CAT734.01+8.77 (+1.21%) ▲|CL93.58-0.96 (-1.02%) ▼|CMCSA21.80-0.57 (-2.53%) ▼|COF209.72+8.16 (+4.05%) ▲|COP146.24+0.29 (+0.20%) ▲|COST990.15-4.46 (-0.45%) ▼|CRM241.54-0.90 (-0.37%) ▼|CSCO107.36+0.65 (+0.60%) ▲|CVS94.10-0.66 (-0.69%) ▼|CVX226.91+1.20 (+0.53%) ▲|DE628.79-3.41 (-0.54%) ▼|DHR228.90+4.66 (+2.08%) ▲|DIS110.58-1.09 (-0.98%) ▼|DUK121.17-0.16 (-0.13%) ▼|EMR161.89+1.43 (+0.89%) ▲|FDX298.94+0.18 (+0.06%) ▲|GD345.69+1.25 (+0.36%) ▲|GE304.97+5.10 (+1.70%) ▲|GEV921.39+31.06 (+3.49%) ▲|GILD152.75-3.76 (-2.40%) ▼|GM75.77-1.32 (-1.71%) ▼|GOOG327.00-9.40 (-2.79%) ▼|GOOGL331.07-9.21 (-2.71%) ▼|GS891.05+6.24 (+0.70%) ▲|HD313.58-1.53 (-0.48%) ▼|HON214.76+1.44 (+0.67%) ▲|IBM244.12+2.20 (+0.91%) ▲|INTC91.80+0.11 (+0.11%) ▲|INTU333.34-1.96 (-0.58%) ▼|ISRG418.37-19.63 (-4.48%) ▼|JNJ255.38-3.99 (-1.54%) ▼|JPM333.44-1.82 (-0.54%) ▼|KO92.86-0.64 (-0.68%) ▼|LIN500.09-1.80 (-0.36%) ▼|LLY1,266.98-16.68 (-1.30%) ▼|LMT548.71+0.00 (+0.00%) ▲|LOW195.92-1.36 (-0.69%) ▼|LRCX265.10+1.65 (+0.63%) ▲|MA621.11+0.69 (+0.11%) ▲|MCD244.10-2.42 (-0.98%) ▼|MDLZ63.16-0.83 (-1.30%) ▼|MDT93.77-0.87 (-0.91%) ▼|META704.66+10.41 (+1.50%) ▲|MMM170.67-0.70 (-0.41%) ▼|MO74.12-0.53 (-0.70%) ▼|MRK148.65+0.35 (+0.24%) ▲|MS181.69+1.29 (+0.72%) ▲|MSFT529.51-2.36 (-0.44%) ▼|MU904.87+8.80 (+0.98%) ▲|NEE78.56-0.30 (-0.38%) ▼|NFLX65.92-2.77 (-4.03%) ▼|NKE37.57-0.32 (-0.83%) ▼|NOW151.90+2.36 (+1.57%) ▲|NVDA218.12+1.65 (+0.76%) ▲|ORCL129.46-1.68 (-1.28%) ▼|PEP134.35+0.33 (+0.25%) ▲|PFE29.88-0.24 (-0.78%) ▼|PG157.97-1.35 (-0.85%) ▼|PLTR196.90+4.30 (+2.23%) ▲|PM196.25-3.66 (-1.83%) ▼|QCOM176.25+0.54 (+0.31%) ▲|RTX191.35-1.99 (-1.03%) ▼|SBUX98.62-0.75 (-0.75%) ▼|SCHW91.23+0.34 (+0.37%) ▲|SO90.40-0.32 (-0.35%) ▼|SPG205.54-1.46 (-0.70%) ▼|T22.01-1.41 (-6.02%) ▼|TMO690.98+3.61 (+0.53%) ▲|TMUS153.72-4.04 (-2.56%) ▼|TSLA386.41+12.70 (+3.40%) ▲|TXN282.60+4.82 (+1.73%) ▲|UBER68.42-0.52 (-0.75%) ▼|UNH417.07-2.19 (-0.52%) ▼|UNP290.03+2.42 (+0.84%) ▲|UPS99.03+0.51 (+0.51%) ▲|USB59.03-0.06 (-0.10%) ▼|V407.04+0.47 (+0.12%) ▲|VZ43.39-1.16 (-2.59%) ▼|WFC81.86-0.34 (-0.41%) ▼|WMT117.51-0.34 (-0.29%) ▼|XOM177.96+0.10 (+0.06%) ▲|AAPL341.15+1.65 (+0.49%) ▲|ABBV286.36-2.60 (-0.90%) ▼|ABT99.16-3.29 (-3.21%) ▼|ACN239.63+0.51 (+0.21%) ▲|ADBE256.33-0.40 (-0.16%) ▼|AMAT407.98+3.00 (+0.74%) ▲|AMD542.98+8.24 (+1.54%) ▲|AMGN436.48-2.46 (-0.56%) ▼|AMT179.77-3.79 (-2.06%) ▼|AMZN260.04-2.59 (-0.99%) ▼|AVGO333.80-0.57 (-0.17%) ▼|AXP321.75+3.41 (+1.07%) ▲|BA191.87+1.40 (+0.74%) ▲|BAC50.73+0.09 (+0.18%) ▲|BKNG157.99-5.93 (-3.62%) ▼|BLK1,132.51+3.83 (+0.34%) ▲|BMY61.25-0.44 (-0.71%) ▼|BNY145.28+1.03 (+0.71%) ▲|BRK-B541.72+1.90 (+0.35%) ▲|C122.60+0.09 (+0.07%) ▲|CAT734.01+8.77 (+1.21%) ▲|CL93.58-0.96 (-1.02%) ▼|CMCSA21.80-0.57 (-2.53%) ▼|COF209.72+8.16 (+4.05%) ▲|COP146.24+0.29 (+0.20%) ▲|COST990.15-4.46 (-0.45%) ▼|CRM241.54-0.90 (-0.37%) ▼|CSCO107.36+0.65 (+0.60%) ▲|CVS94.10-0.66 (-0.69%) ▼|CVX226.91+1.20 (+0.53%) ▲|DE628.79-3.41 (-0.54%) ▼|DHR228.90+4.66 (+2.08%) ▲|DIS110.58-1.09 (-0.98%) ▼|DUK121.17-0.16 (-0.13%) ▼|EMR161.89+1.43 (+0.89%) ▲|FDX298.94+0.18 (+0.06%) ▲|GD345.69+1.25 (+0.36%) ▲|GE304.97+5.10 (+1.70%) ▲|GEV921.39+31.06 (+3.49%) ▲|GILD152.75-3.76 (-2.40%) ▼|GM75.77-1.32 (-1.71%) ▼|GOOG327.00-9.40 (-2.79%) ▼|GOOGL331.07-9.21 (-2.71%) ▼|GS891.05+6.24 (+0.70%) ▲|HD313.58-1.53 (-0.48%) ▼|HON214.76+1.44 (+0.67%) ▲|IBM244.12+2.20 (+0.91%) ▲|INTC91.80+0.11 (+0.11%) ▲|INTU333.34-1.96 (-0.58%) ▼|ISRG418.37-19.63 (-4.48%) ▼|JNJ255.38-3.99 (-1.54%) ▼|JPM333.44-1.82 (-0.54%) ▼|KO92.86-0.64 (-0.68%) ▼|LIN500.09-1.80 (-0.36%) ▼|LLY1,266.98-16.68 (-1.30%) ▼|LMT548.71+0.00 (+0.00%) ▲|LOW195.92-1.36 (-0.69%) ▼|LRCX265.10+1.65 (+0.63%) ▲|MA621.11+0.69 (+0.11%) ▲|MCD244.10-2.42 (-0.98%) ▼|MDLZ63.16-0.83 (-1.30%) ▼|MDT93.77-0.87 (-0.91%) ▼|META704.66+10.41 (+1.50%) ▲|MMM170.67-0.70 (-0.41%) ▼|MO74.12-0.53 (-0.70%) ▼|MRK148.65+0.35 (+0.24%) ▲|MS181.69+1.29 (+0.72%) ▲|MSFT529.51-2.36 (-0.44%) ▼|MU904.87+8.80 (+0.98%) ▲|NEE78.56-0.30 (-0.38%) ▼|NFLX65.92-2.77 (-4.03%) ▼|NKE37.57-0.32 (-0.83%) ▼|NOW151.90+2.36 (+1.57%) ▲|NVDA218.12+1.65 (+0.76%) ▲|ORCL129.46-1.68 (-1.28%) ▼|PEP134.35+0.33 (+0.25%) ▲|PFE29.88-0.24 (-0.78%) ▼|PG157.97-1.35 (-0.85%) ▼|PLTR196.90+4.30 (+2.23%) ▲|PM196.25-3.66 (-1.83%) ▼|QCOM176.25+0.54 (+0.31%) ▲|RTX191.35-1.99 (-1.03%) ▼|SBUX98.62-0.75 (-0.75%) ▼|SCHW91.23+0.34 (+0.37%) ▲|SO90.40-0.32 (-0.35%) ▼|SPG205.54-1.46 (-0.70%) ▼|T22.01-1.41 (-6.02%) ▼|TMO690.98+3.61 (+0.53%) ▲|TMUS153.72-4.04 (-2.56%) ▼|TSLA386.41+12.70 (+3.40%) ▲|TXN282.60+4.82 (+1.73%) ▲|UBER68.42-0.52 (-0.75%) ▼|UNH417.07-2.19 (-0.52%) ▼|UNP290.03+2.42 (+0.84%) ▲|UPS99.03+0.51 (+0.51%) ▲|USB59.03-0.06 (-0.10%) ▼|V407.04+0.47 (+0.12%) ▲|VZ43.39-1.16 (-2.59%) ▼|WFC81.86-0.34 (-0.41%) ▼|WMT117.51-0.34 (-0.29%) ▼|XOM177.96+0.10 (+0.06%) ▲|
10.7 C
New York
Wednesday, October 21, 2026

Tag: 0001

newsFORsourcecompanycontentinformation1releasesmarket

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

Anterix Inc. Reports Full Fiscal Year 2026 Results

WOODLAND PARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2026.

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion...

Châtillon, France, le 8 juin (22 :30 CET) 2026

DEMIRE: Großaktionäre starten strukturierten Verkaufsprozess

DEMIRE: Großaktionäre starten strukturierten Verkaufsprozess

DEMIRE: Major shareholders launch structured sale process

DEMIRE: Major shareholders launch structured sale process

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags0001

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers